trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Bayart E et al. A major role for mitotic CDC2 kinase inactivation in the establishment of the mitotic DNA damage checkpoint. 2004 Cancer Res. pmid:15604258
Zhao LY et al. An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. 2006 Cancer Res. pmid:17018599
Yang X et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. 2001 Cancer Res. pmid:11585728
Luo W et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. 2010 Cancer Res. pmid:20587525
Sasaki Y et al. p53 negatively regulates the hepatoma growth factor HDGF. 2011 Cancer Res. pmid:22006999
Phan D et al. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. 2004 Cancer Res. pmid:15126343
Wei M et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. 2005 Cancer Res. pmid:16322213
Mariadason JM et al. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. 2000 Cancer Res. pmid:10969808
James SY et al. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. 2003 Cancer Res. pmid:12839938
Noh EJ et al. Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells. 2005 Cancer Res. pmid:16357148
Terui T et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. 2003 Cancer Res. pmid:14695212
Setiadi AF et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. 2008 Cancer Res. pmid:19047136
Sharma D et al. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. 2006 Cancer Res. pmid:16778215
Shi J et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. 2007 Cancer Res. pmid:17616702
Qi H and Ratnam M Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. 2006 Cancer Res. pmid:16740727
Yoshida M et al. Effects of trichostatins on differentiation of murine erythroleukemia cells. 1987 Cancer Res. pmid:2439196
Singal R et al. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. 2001 Cancer Res. pmid:11406558
Brest P et al. Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET. 2007 Cancer Res. pmid:18056459
Maecker HL et al. p53 promotes selection for Fas-mediated apoptotic resistance. 2000 Cancer Res. pmid:10969818
Su GH et al. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. 2000 Cancer Res. pmid:10866300
Blagosklonny MV et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. 2005 Cancer Res. pmid:16103091
Lin F et al. Unique anti-activator protein-1 activity of retinoic acid receptor beta. 2000 Cancer Res. pmid:10866321
Sirchia SM et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. 2002 Cancer Res. pmid:11980632
Hsu PY et al. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. 2009 Cancer Res. pmid:19549897
Heller G et al. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. 2008 Cancer Res. pmid:18172295
Shin JY et al. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. 2000 Cancer Res. pmid:10667572
Kretzner L et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. 2011 Cancer Res. pmid:21502403
Medina V et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. 1997 Cancer Res. pmid:9288776
Harada K et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. 2002 Cancer Res. pmid:12384554
Wilson AJ et al. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. 2002 Cancer Res. pmid:12414619
Ho WC et al. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. 2005 Cancer Res. pmid:15899819
Tran T et al. Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. 2005 Cancer Res. pmid:15899836
Kim MS et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. 2003 Cancer Res. pmid:14612526
Majid S et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. 2010 Cancer Res. pmid:20332239
Liu LT et al. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. 2003 Cancer Res. pmid:12810630
Allison SJ and Milner J Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidy. 2003 Cancer Res. pmid:14583461
Lin YC et al. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. 2008 Cancer Res. pmid:18381445
Wang J et al. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. 1999 Cancer Res. pmid:10383127
Kim TY et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. 2006 Cancer Res. pmid:16885346
Ferrara FF et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. 2001 Cancer Res. pmid:11196162
Zhao S et al. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. 2003 Cancer Res. pmid:12750289
Nishigaki M et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. 2005 Cancer Res. pmid:15781621
Bai J et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. 2005 Cancer Res. pmid:15781649
Yang X et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. 2000 Cancer Res. pmid:11156387
Rahmani M et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. 2005 Cancer Res. pmid:15781658
Stiehl DP et al. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. 2007 Cancer Res. pmid:17332356
Kim M et al. LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer. 2008 Cancer Res. pmid:18757430
Mori T et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. 2005 Cancer Res. pmid:15753377
Nervi C et al. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. 2001 Cancer Res. pmid:11245412
Zhu WG et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. 2001 Cancer Res. pmid:11245429